Sigyn Therapeutics (SIGY) Other Accumulated Expenses (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Other Accumulated Expenses of $3932.0 for Q3 2025, up 15.38% sequentially from $3408.0 in Q2 2025, and up 8091.67% YoY from $48.0 in Q3 2024.
Sigyn Therapeutics (SIGY) Other Accumulated Expenses (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Other Accumulated Expenses for 10 years, with the latest figure at $3932.0 in Q3 2025.
- Quarterly Other Accumulated Expenses rose 8091.67% year-over-year to $3932.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $3932.0 (up 8091.67% YoY) and the FY2024 annual result came in at $1742.0, down 45.25% from the prior year.
- Other Accumulated Expenses improved to $3932.0 in Q3 2025 per SIGY's latest filing, from $3408.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $29209.0 in Q3 2021 and troughed at $48.0 in Q3 2024.
- A 5-year average of $3454.8 and a median of $1987.0 in 2022 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2021 and 2025: Other Accumulated Expenses plunged 99.02% in 2021, then surged 8091.67% in 2025.
- Over 5 years, Other Accumulated Expenses stood at $179.0 in 2021, then surged by 568.72% to $1197.0 in 2022, then jumped by 165.83% to $3182.0 in 2023, then tumbled by 45.25% to $1742.0 in 2024, then jumped by 125.72% to $3932.0 in 2025.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $3932.0, $3408.0, and $312.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3,932.00 |
| Jun 30, 2025 | 3,408.00 |
| Mar 31, 2025 | 312.00 |
| Dec 31, 2024 | 1,742.00 |
| Sep 30, 2024 | 48.00 |
| Jun 30, 2024 | 2,247.00 |
| Mar 31, 2024 | 2,569.00 |
| Dec 31, 2023 | 3,182.00 |
| Sep 30, 2023 | 1,807.00 |
| Jun 30, 2023 | 2,261.00 |
| Mar 31, 2023 | 1,039.00 |
| Dec 31, 2022 | 1,197.00 |
| Mar 31, 2022 | 1,987.00 |
| Dec 31, 2021 | 179.00 |
| Sep 30, 2021 | 29,209.00 |
| Jun 30, 2021 | 1,435.00 |
| Mar 31, 2021 | 2,178.00 |
| Dec 31, 2020 | 523.00 |
| Sep 30, 2020 | 208,796.00 |
| Jun 30, 2020 | 145,827.00 |